Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627184 | 1.00 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL5228321 | 1.00 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27694646 | 0.84 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL22332007 | 0.82 | KMT2A (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27604046 | 0.82 | TSHR (0.47) | TSHRKMT2AMEN1TAAR1HTT | |
| SCHEMBL8030875 | 0.81 | CA1 (0.51) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13418948 | 0.81 | TSHR (0.54) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL7190391 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT | |
| SCHEMBL3557233 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT | |
| SCHEMBL5229745 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGNERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20190336610-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2019-11-07 | — | — | US | disclosed |
| EP-3558383-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | Gubra ApS (DK) | 2019-10-30 | — | — | EP | disclosed |
| CN-110087690-A | Glucose-sensitive peptide hormone | 古布拉有限公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-106478651-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| EP-3349579-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018115462-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | GUBRA APS (DK) | 2018-06-28 | — | — | WO | disclosed |
| US-9758502-B2 | Dihydropyrone compounds and herbicides comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758502-B2 | Dihydropyrone compounds and herbicides comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-09-12 | — | — | US | disclosed |
| WO-2017048675-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-23 | — | — | WO | disclosed |
| WO-1999051234-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051595-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1998048791-A1 | SYNTHESIS OF DISCODERMOLIDE AND ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998007734-A9 | OLIGONUCLEOTIDE PRODRUGS | — | 1998-04-30 | — | — | WO | disclosed |
| WO-1998007734-A1 | OLIGONUCLEOTIDE PRODRUGS | HYBRIDON, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0779893-A2 | OLIGONUCLEOTIDE PRODRUGS | HYBRIDON, Inc. (US) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007392-A2 | OLIGONUCLEOTIDE PRODRUGS | HYBRIDON, INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0223588-B1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-12 | — | — | EP | disclosed |
| WO-1988001619-A1 | 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-10 | — | — | WO | disclosed |
| EP-0223588-A1 | Process for the preparation of beta-lactam compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | TSHR 3041/4885CA1 949/4885CA2 1524/4885 |
| US-20190336610-A1 | GLUCOSE-SENSITIVE PEPTIDE HORMONES | IAPP, GCG, VIP | TSHR 229/4885CA1 381/4885CA2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.